Drug Type Autologous CAR-T |
Synonyms CD20-CD19 cCAR T cell therapy (iCell Gene Therapeutics) |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingEarly Phase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-Cell Leukemia | Phase 1 | CN | 01 Aug 2018 | |
B-Cell Leukemia | Phase 1 | CN | 01 Aug 2018 | |
B-Cell Lymphoma | Phase 1 | CN | 01 Aug 2018 | |
B-Cell Lymphoma | Phase 1 | CN | 01 Aug 2018 |